Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER (RANGER)
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Sponsor: Biogen
Terminated
The company determined that continued exposure of these high-risk PH patients to clinic or in-person visits during the COVID pandemic presented an unacceptable risk.
Other terminated trials from Biogen
Other Pulmonary Hypertension trials with similar outcome
This PHASE3 trial investigates Pulmonary Hypertension and is currently terminated or withdrawn. Biogen leads this study, which shows 19 recorded versions since 2017 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
19 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Jul 2025 — Sep 2025 [monthly]
Terminated PHASE3
-
Sep 2024 — Jul 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Mar 2024 — Jul 2024 [monthly]
Terminated PHASE3
▶ Show 14 earlier versions
-
Nov 2023 — Mar 2024 [monthly]
Terminated PHASE3
-
Apr 2022 — Nov 2023 [monthly]
Terminated PHASE3
-
Dec 2021 — Apr 2022 [monthly]
Terminated PHASE3
-
Oct 2021 — Dec 2021 [monthly]
Terminated PHASE3
-
Jan 2021 — Oct 2021 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
-
Sep 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Jun 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2019 — Jun 2020 [monthly]
Recruiting PHASE3
-
Oct 2018 — Sep 2019 [monthly]
Recruiting PHASE3
-
Jul 2018 — Oct 2018 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE3
-
Aug 2017 — Jun 2018 [monthly]
Recruiting PHASE3
-
May 2017 — Aug 2017 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Mar 2017 — May 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Biogen
For direct contact, visit the study record on ClinicalTrials.gov .